Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 11:38AM ET
0.6050
Dollar change
+0.0250
Percentage change
4.31
%
Index- P/E- EPS (ttm)-11.87 Insider Own5.94% Shs Outstand23.69M Perf Week7.08%
Market Cap14.33M Forward P/E- EPS next Y-0.82 Insider Trans0.00% Shs Float22.28M Perf Month7.98%
Income-114.83M PEG- EPS next Q-0.22 Inst Own12.26% Short Float1.36% Perf Quarter5.77%
Sales8.12M P/S1.77 EPS this Y33.43% Inst Trans-25.23% Short Ratio2.43 Perf Half Y-9.51%
Book/sh0.85 P/B0.71 EPS next Y87.56% ROA-83.55% Short Interest0.30M Perf Year-93.27%
Cash/sh1.50 P/C0.40 EPS next 5Y- ROE-219.79% 52W Range0.45 - 10.47 Perf YTD2.98%
Dividend Est.- P/FCF- EPS past 5Y13.00% ROI-538.79% 52W High-94.22% Beta1.91
Dividend TTM- Quick Ratio0.55 Sales past 5Y-13.77% Gross Margin-91.94% 52W Low34.44% ATR (14)0.04
Dividend Ex-Date- Current Ratio0.65 EPS Y/Y TTM7.95% Oper. Margin-792.77% RSI (14)54.60 Volatility5.19% 5.67%
Employees190 Debt/Eq2.65 Sales Y/Y TTM833.56% Profit Margin-1413.77% Recom2.00 Target Price6.00
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q65.63% Payout- Rel Volume0.48 Prev Close0.58
Sales Surprise-50.01% EPS Surprise-171.43% Sales Q/Q1989.59% EarningsNov 14 AMC Avg Volume124.77K Price0.61
SMA204.06% SMA50-1.15% SMA200-34.68% Trades Volume21,552 Change4.31%
Date Action Analyst Rating Change Price Target Change
Nov-11-22Downgrade Raymond James Strong Buy → Outperform $5 → $2
Dec-29-21Resumed Jefferies Buy $7 → $6
Feb-25-21Initiated Jefferies Buy $7
Aug-27-20Upgrade Raymond James Outperform → Strong Buy $8 → $9
Jan-16-19Initiated Oppenheimer Outperform $9
Nov-01-17Initiated Canaccord Genuity Buy $10
Oct-10-16Initiated Laidlaw Buy $6
Jul-26-16Initiated Ladenburg Thalmann Buy
May-07-15Initiated Noble Financial Buy $7
Mar-22-24 07:00AM
Feb-14-24 12:48PM
07:00AM
Feb-13-24 07:04PM
Nov-20-23 08:00AM
04:05PM Loading…
Nov-14-23 04:05PM
Oct-26-23 08:00AM
Sep-27-23 07:30AM
Sep-07-23 08:00AM
Sep-06-23 08:00AM
Aug-14-23 08:00AM
Aug-03-23 06:25PM
Jul-24-23 08:00AM
Jul-19-23 08:00AM
Jul-13-23 07:00AM
09:00AM Loading…
Jul-06-23 09:00AM
Jul-05-23 04:12PM
04:01PM
Jun-23-23 04:05PM
Jun-15-23 08:00AM
Jun-07-23 08:00AM
Jun-04-23 09:32AM
May-15-23 09:25AM
08:00AM
May-03-23 10:00AM
May-01-23 10:00AM
Apr-25-23 08:00AM
Apr-05-23 11:42AM
Apr-04-23 01:55PM
08:00AM
06:37AM Loading…
Mar-15-23 06:37AM
Mar-13-23 09:15AM
08:00AM
Feb-23-23 08:00AM
Feb-15-23 08:00AM
Jan-24-23 06:16AM
Dec-08-22 08:00AM
Dec-06-22 09:25AM
Nov-22-22 08:00AM
Nov-14-22 08:00AM
Nov-11-22 08:00AM
Nov-10-22 09:15AM
08:00AM
Nov-08-22 06:25PM
Nov-03-22 06:35PM
Oct-17-22 08:00AM
Oct-13-22 11:23AM
Oct-12-22 10:38AM
08:00AM
Sep-29-22 08:00AM
Sep-21-22 08:00AM
Sep-15-22 08:30AM
Sep-08-22 01:00AM
Aug-08-22 09:15AM
08:00AM
Aug-04-22 08:25AM
Jul-19-22 09:25AM
Jul-14-22 12:30PM
Jul-12-22 08:00AM
Jun-28-22 08:00AM
Jun-22-22 04:06PM
08:00AM
Jun-07-22 08:00AM
Jun-06-22 08:00AM
Jun-01-22 08:00AM
May-26-22 08:00AM
May-19-22 08:00AM
May-12-22 07:12AM
May-09-22 09:15AM
08:00AM
May-05-22 05:55PM
May-02-22 08:00AM
Apr-28-22 08:00AM
Apr-11-22 12:19PM
Apr-05-22 12:20PM
08:00AM
Mar-29-22 08:00AM
Mar-15-22 08:00AM
Mar-07-22 09:15AM
08:00AM
07:57AM
Feb-25-22 08:30AM
Feb-23-22 04:05PM
08:45AM
Feb-09-22 12:06PM
Jan-26-22 08:00AM
Jan-19-22 08:04PM
Jan-05-22 08:00AM
Dec-29-21 10:53AM
Dec-09-21 08:00AM
Dec-07-21 07:25AM
Dec-01-21 04:15PM
07:30AM
Nov-29-21 12:25PM
Nov-16-21 08:00AM
Nov-08-21 09:25AM
08:00AM
Nov-01-21 08:00AM
Oct-25-21 03:01PM
Oct-15-21 08:49AM
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILLIS STEVENDirectorJul 10 '23Buy1.65609,0901,004,9981,043,292Jul 18 09:00 AM
PERCEPTIVE ADVISORS LLC10% OwnerApr 06 '23Sale0.114,251,563467,67241,440,729Apr 06 05:51 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 05 '23Sale0.131,832,563238,23345,691,816Apr 06 05:51 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 04 '23Sale0.164,810,623769,70047,524,379Apr 06 05:51 PM